Trials / Completed
CompletedNCT07498413
Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 218,677 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study was to describe the epidemiology, treatment pathway, treatment access, wastage of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), and health care resource use among adults with hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer (BC) in England, including their treatment pathway leading to progression to metastatic BC for those who were initially diagnosed with early BC. This was a retrospective cohort study using linked registry and administrative data.
Conditions
Timeline
- Start date
- 2023-06-08
- Primary completion
- 2025-07-18
- Completion
- 2025-07-18
- First posted
- 2026-03-27
- Last updated
- 2026-04-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT07498413. Inclusion in this directory is not an endorsement.